Status:
COMPLETED
Modulation Effects of Baduanjin Exercise on Subjective Cognitive Decline
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Cognitive Decline
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
The aim of this study is to investigate the modulation effects of Baduanjin (BDJ), a simple and innovative mind-body exercise, on cognitive function, resting state functional connectivity, and brain m...
Detailed Description
Subjective cognitive decline (SCD), the self-reported perception of memory or cognitive problems, is receiving increasing attention as a risk factor for the development of Alzheimer's disease (AD). Si...
Eligibility Criteria
Inclusion
- 50 - 80 years old
- Self-reported experience of persistent decline in memory compared with a previous state (within the past 5 years), which was further confirmed by informants
- Concerns regarding memory problems
- Mini-Mental State Examination, Second Edition (MMSE-2) scores within the normal range
- Montreal Cognitive Assessment scores within the normal range (adjusted for age, sex, and education)
- Clinical Dementia Rating score of 0 (no memory loss or slight, inconsistent forgetfulness)
Exclusion
- Unable to speak or read English
- Diagnosis of depression
- Other diseases that cause cognitive decline (e.g., traumatic brain injury, stroke, neurodegenerative diseases, brain tumor, Parkinson disease, encephalitis or epilepsy, thyroid dysfunction, severe anemia, syphilis)
- History of psychosis or congenital mental growth retardation
- Any delayed recall index greater than 1.5 SD below average on the California Verbal Learning Test, Second Edition
- Failing the Memory items on the MMSE-2 and MDRS-2, as well as the CVLT-II criterion
- Inability to participate in a 6-month intervention with a 3-month follow-up
- Any item = 0 on the Lawton-Brody Instrumental Activities of Daily Living Scale for cognitive reasons
- No available informant
- Previous diagnosis of MCI, AD, or other age-related dementia
- Previous Baduanjin experience
Key Trial Info
Start Date :
August 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 6 2025
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT04009382
Start Date
August 31 2020
End Date
February 6 2025
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129